Vestra
Executive Summary
P&U receives second "approvable" letter for the reboxetine antidepressant Feb. 23. P&U said it conducted two U.S. trials for Vestra to supplement the non-U.S. data in its NDA following the first "approvable" letter in July, but only one showed efficacy on the primary endpoint (1"The Pink Sheet" Feb. 14, p. 29)